Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;12(4):R58.
doi: 10.1186/bcr2620. Epub 2010 Aug 3.

Breast cancer incidence and overdiagnosis in Catalonia (Spain)

Affiliations

Breast cancer incidence and overdiagnosis in Catalonia (Spain)

Montserrat Martinez-Alonso et al. Breast Cancer Res. 2010.

Abstract

Introduction: Early detection of breast cancer (BC) with mammography may cause overdiagnosis and overtreatment, detecting tumors which would remain undiagnosed during a lifetime. The aims of this study were: first, to model invasive BC incidence trends in Catalonia (Spain) taking into account reproductive and screening data; and second, to quantify the extent of BC overdiagnosis.

Methods: We modeled the incidence of invasive BC using a Poisson regression model. Explanatory variables were: age at diagnosis and cohort characteristics (completed fertility rate, percentage of women that use mammography at age 50, and year of birth). This model also was used to estimate the background incidence in the absence of screening. We used a probabilistic model to estimate the expected BC incidence if women in the population used mammography as reported in health surveys. The difference between the observed and expected cumulative incidences provided an estimate of overdiagnosis.

Results: Incidence of invasive BC increased, especially in cohorts born from 1940 to 1955. The biggest increase was observed in these cohorts between the ages of 50 to 65 years, where the final BC incidence rates more than doubled the initial ones. Dissemination of mammography was significantly associated with BC incidence and overdiagnosis. Our estimates of overdiagnosis ranged from 0.4% to 46.6%, for women born around 1935 and 1950, respectively.

Conclusions: Our results support the existence of overdiagnosis in Catalonia attributed to mammography usage, and the limited malignant potential of some tumors may play an important role. Women should be better informed about this risk. Research should be oriented towards personalized screening and risk assessment tools.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Steps for estimating overdiagnosis for cohort 1950. See Appendix E.1 in Additional file 1 for a detailed description.
Figure 2
Figure 2
Completed fertility rate (CFR) and proportion having periodic mammograms at age 50 (PM50).
Figure 3
Figure 3
Observed breast cancer (BC) incidence rates per 100,000 women (points) and the fitted model (lines). Each color represents a cohort of birth.
Figure 4
Figure 4
Breast cancer (BC) incidence model for screening and background scenarios. Each plot shows the results for cohorts born in 1935, 1940, 1945 and 1950: observed BC incident rates per 100,000 women (points), model with (dashed blue line) and without (purple line) screening. Confidence intervals were obtained using bootstrap.
Figure 5
Figure 5
Predicted breast cancer incidence rates per 100,000 women at birth. Each plot shows the results for cohorts born in 1935, 1940, 1945 and 1950: observed (points), background scenario (dashed gray line), and scenario that takes into account the actual dissemination of mammography (purple line).

Similar articles

Cited by

References

    1. Kelsey J, Gammon M. The epidemiology of breast cancer. CA Cancer J Clin. 1991;41:146–165. doi: 10.3322/canjclin.41.3.146. - DOI - PubMed
    1. Kelsey J, Gammon M, John E. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15:36–47. - PubMed
    1. Beral V, Banks E, Reeves G, Wallis M. Hormone replacement therapy and high incidence of breast cancer between mammographic screens. Lancet. 1997;349:1103–1104. doi: 10.1016/S0140-6736(05)62328-8. - DOI - PubMed
    1. van den Brandt P, Spiegelman D, Yaun S, Adami H, Beeson L, Folsom A, Fraser G, Goldbohm R, Graham S, Kushi L, Marshall JR, Miller A, Rohan T, Smith-Warner S, Speizer F, Willett WC, Wolk A, Hunter DJ. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152:514–527. doi: 10.1093/aje/152.6.514. - DOI - PubMed
    1. Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M, Jackson R, Beresford S, Howard B, Johnson K, Kotchen J, Ockene J. for the Women's Health Initiative Investigators WG. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. doi: 10.1001/jama.288.3.321. - DOI - PubMed

Publication types